Literature DB >> 3118189

Differential promoter utilization by the c-myc gene in mitogen- and interleukin-2-stimulated human lymphocytes.

H E Broome1, J C Reed, E P Godillot, R G Hoover.   

Abstract

Transcription of the c-myc gene is initiated from two principal promoters, P1 and P2. We demonstrate here that a shift in promoter utilization occurred with time in human peripheral blood mononuclear cells (PBMC) that had been stimulated to proliferate. The P1/P2 ratio reached a maximum of approximately 1.3 at 4 h after phytohemagglutinin stimulation and a minimum of 0.31 at 48 h. Actinomycin decay experiments demonstrated that both P1 and P2 transcripts had similar half-lives at early and late times after mitogen stimulation, indicating that the shift in promoter utilization was probably not posttranscriptionally regulated. Addition of interleukin-2 to previously activated PBMC increased c-myc mRNA, but unlike increases after mitogen stimulation, the P1/P2 ratio stayed less than 0.5. Our findings demonstrated that there was a difference between mitogen- and interleukin-2-stimulated increases in c-myc RNA in PBMC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118189      PMCID: PMC367921          DOI: 10.1128/mcb.7.8.2988-2993.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  Expression of a receptor for IgM by human T cells in vitro.

Authors:  L Moretta; M Ferrarini; M L Durante; M C Mingari
Journal:  Eur J Immunol       Date:  1975-08       Impact factor: 5.532

2.  Kinetics of human lymphocyte proliferation: proportion of cells responsive to phytohemagglutinin and correlation with E rosette formation.

Authors:  P C Nowell; R P Daniele; L A Winger
Journal:  J Reticuloendothel Soc       Date:  1975-01

3.  Deregulation of the c-myc oncogene in virus-induced thymic lymphomas of AKR/J mice.

Authors:  A Reicin; J Q Yang; K B Marcu; E Fleissner; C F Koehne; P V O'Donnell
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line.

Authors:  S Collins; M Groudine
Journal:  Nature       Date:  1982-08-12       Impact factor: 49.962

6.  Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient.

Authors:  R Dalla-Favera; F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

7.  RNA processing errors in patients with beta-thalassemia.

Authors:  T J Ley; N P Anagnou; G Pepe; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas.

Authors:  J M Adams; S Gerondakis; E Webb; L M Corcoran; S Cory
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

9.  The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.

Authors:  J Battey; C Moulding; R Taub; W Murphy; T Stewart; H Potter; G Lenoir; P Leder
Journal:  Cell       Date:  1983-10       Impact factor: 41.582

10.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

Authors:  R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more
  8 in total

1.  Expression, regulation, and chromosomal localization of the Max gene.

Authors:  A J Wagner; M M Le Beau; M O Diaz; N Hay
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

2.  Post-transcriptional control of c-myc proto-oncogene expression by glucocorticoid hormones in human T lymphoblastic leukemic cells.

Authors:  M Maroder; S Martinotti; A Vacca; I Screpanti; E Petrangeli; L Frati; A Gulino
Journal:  Nucleic Acids Res       Date:  1990-03-11       Impact factor: 16.971

3.  Two distinct mechanisms of transcriptional control operate on c-myc during differentiation of HL60 cells.

Authors:  U Siebenlist; P Bressler; K Kelly
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Repeated CT elements bound by zinc finger proteins control the absolute and relative activities of the two principal human c-myc promoters.

Authors:  E DesJardins; N Hay
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

5.  c-myc RNA degradation in growing and differentiating cells: possible alternate pathways.

Authors:  S G Swartwout; A J Kinniburgh
Journal:  Mol Cell Biol       Date:  1989-01       Impact factor: 4.272

6.  Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.

Authors:  R G Hoover; C Lary; R Page; P Travis; R Owens; J Flick; J Kornbluth; B Barlogie
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

7.  Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype.

Authors:  Feimeng Zheng; Caifeng Yue; Guohui Li; Bin He; Wei Cheng; Xi Wang; Min Yan; Zijie Long; Wanshou Qiu; Zhongyu Yuan; Jie Xu; Bing Liu; Qian Shi; Eric W-F Lam; Mien-Chie Hung; Quentin Liu
Journal:  Nat Commun       Date:  2016-01-19       Impact factor: 14.919

8.  Selective Activation of Alternative MYC Core Promoters by Wnt-Responsive Enhancers.

Authors:  Jorge A Bardales; Evin Wieser; Hideya Kawaji; Yasuhiro Murakawa; Xavier Darzacq
Journal:  Genes (Basel)       Date:  2018-05-23       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.